Get the Stockscreener App
1.99
30.92%
0.47
After Hours:
1.95
-0.04
-2.01%
Imunon Inc stock is traded at $1.99, with a volume of 23.89M.
It is up +30.92% in the last 24 hours and up +125.75% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$1.52
Open:
$1.78
24h Volume:
23.89M
Relative Volume:
2.77
Market Cap:
$34.90M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-1.0529
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+378.94%
1M Performance:
+125.75%
6M Performance:
+136.06%
1Y Performance:
+34.46%
1-Day Range:
$1.60
$2.23
1-Week Range:
$0.85
$2.40
52-Week Range:
$0.37
$3.65
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.99 | 7.29M | 500.00K | -19.45M | -18.22M | -1.89 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Imunon Inc Stock (IMNN) Latest News
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Insider Monkey
IMUNON’s Stacy Lindborg on the long road to Phase III - The Pharma Letter
IMUNON Closes Up To $9.75 Million Private Placement Priced At-Th - GuruFocus
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development - Stock Titan
Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon By Stocktwits - Investing.com India
Imunon (IMNN) Gains Attention with Upcoming ESMO Presentation | - GuruFocus
IMUNON, Inc. to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - marketscreener.com
IMNN's Immune Biomarker Data to be Highlighted at ESMO 2025 | IM - GuruFocus
Imunon announces up to $9.75M private placement priced at-the-market - Yahoo Finance
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 | IMNN Stock News - GuruFocus
IMUNON Invited to Present Translational Data in Supporting - GlobeNewswire
Breakthrough Ovarian Cancer Drug Extends Life by 13 Months in Phase 2 Trial: Key Data Coming to ESMO - Stock Titan
Imunon Announces Private Placement Agreement with Investors - TipRanks
3 Penny Stocks to Watch Now, 5/27/25 - TipRanks
IMUNON launches up to $9.75M securities offering - MSN
Imunon (IMNN) Reveals Private Placement Plans with Potential for - GuruFocus
IMUNON (IMNN) Plans $3.25M Capital Raise Through Share Offering - GuruFocus
Best Biotech Stocks To Follow Today – May 23rd - Defense World
Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga
IMUNON Announces Up To $9.75 Million Private Placement Priced At - GuruFocus
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules | IMNN Stock News - GuruFocus
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
DNA Immunotherapy Developer IMUNON Raises $9.75M to Advance Phase 3 Clinical Program - Stock Titan
Big Gains For Imunon, Merus, And Douglas Elliman - Finimize
Biotech Stock Surges To Close The Week After Major Announcement - The Globe and Mail
IMUNON’s Game-Changing Ovarian Cancer Data Sparks Massive Stock Surge – Here’s What You Need to Know! - RagingBull
Imunon Stock (IMNN) Rockets on Clinical Trial Results - TipRanks
Imunon shares soar on promising ovarian cancer trial results By Investing.com - Investing.com Nigeria
Imunon shares soar on promising ovarian cancer trial results - Investing.com
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell - marketscreener.com
IMNN Announces Promising Phase 2 Results for Ovarian Cancer Ther - GuruFocus
IMNN Announces Promising Phase 2 Results for Ovarian Cancer Therapy | IMNN Stock News - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation High - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer | IMNN Stock - GuruFocus
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation - GlobeNewswire
Breakthrough: New Ovarian Cancer Drug Extends Patient Survival by 13 Months in Groundbreaking Trial Results - Stock Titan
Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’ By Stocktwits - Investing.com India
Imunon announces withdrawal of Form S-1 Registration Statement - TipRanks
IMUNON Announces Withdrawal of Form S-1 Registration Statement | - GuruFocus
Imunon (IMNN) Withdraws SEC Registration for Planned Public Offe - GuruFocus
Imunon, Inc. announced that it expects to receive $3.25 million in funding - marketscreener.com
IMUNON Announces Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Phase 3 Biotech IMUNON Halts Public Offering Plans: What This Means for DNA Immunotherapy Pipeline - Stock Titan
Imunon withdraws public offering registration By Investing.com - Investing.com Nigeria
Imunon Withdraws Registration Statement Impacting Strategy - TipRanks
Imunon withdraws public offering registration - Investing.com
Imunon faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Imunon (NASDAQ:IMNN) Rating Lowered to “Hold” at D Boral Capital - Defense World
Imunon Receives Nasdaq Non-Compliance Notice - TipRanks
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imunon Inc Stock (IMNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Aug 15 '24 |
Buy |
0.98 |
25,000 |
24,500 |
264,166 |
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):